Beckman Coulter, Lumigen make it official
This article was originally published in The Gray Sheet
Executive Summary
Beckman Coulter gains access to Lumigen's technology for immunochemical and other high-sensitivity testing via its $185 mil. acquisition, expected to close by Nov. 1. Having partnered with Lumigen for more than 10 years, Beckman Coulter has already drawn from the company's well; Lumigen's chemiluminescent chemistry is the cornerstone of Beckman Coulter's Access family of immunoassay systems, the Oct. 2 release says...